Evidence map›Paper›PMID 40774158›Full record

Trial reportSleep medicine2025

Effect of tirzepatide treatment on patient-reported outcomes among SURMOUNT-OSA participants with obstructive sleep apnea and obesity.

Chisom Kanu, Shraddha Shinde, Sujatro Chakladar, Ellen B Dennehy, Terri E Weaver, Jiat Ling Poon, Atul Malhotra

Registry-linked trialAbstract readRandomized Controlled TrialClinical Trial, Phase III
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Sleep medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT05412004. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05412004 phase3completed

A Master Protocol to Investigate the Efficacy and Safety of Tirzepatide Once Weekly in Participants Who Have Obstructive Sleep Apnea and Obesity: A Randomized, Double-Blind, Placebo-Controlled Trial

Ran2022Enrolled469Registered outcomes9Posted comparisons20ConditionsObesity, Obstructive Sleep ApneaArmsPlacebo, Tirzepatide
Open the trial in the graph
3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Should weight loss be the first-line treatment for obstructive sleep apnoea? A pro-con debate.European respiratory review : an official journal of the European Respiratory Society · 2026
    Review
  6. Review
  7. Treatment preferences for comorbid obesity and obstructive sleep apnea (PRO-CON OSA) survey: Patient and provider preferences for CPAP and/or tirzepatide.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Chisom KanuEli Lilly and Company, Indianapolis, IN, USA. Electronic address: kanu_chisom@lilly.com.
Shraddha ShindeEli Lilly and Company, Indianapolis, IN, USA.
Sujatro ChakladarEli Lilly and Company, Indianapolis, IN, USA.
Ellen B DennehyEli Lilly and Company, Indianapolis, IN, USA.
Terri E WeaverCollege of Nursing, University of Illinois Chicago, Chicago, IL, USA; University of Pennsylvania School of Nursing, Philadelphia, PA, USA.
Jiat Ling PoonEli Lilly and Company, Indianapolis, IN, USA.
Atul MalhotraUniversity of California San Diego, La Jolla, CA, USA.

Funding

The cardiovascular consequences of sleep apnea plus COPD (Overlap syndrome)R01HL166485 · UNIVERSITY OF CALIFORNIA, SAN DIEGO · 2025 to 2025
$776k
Developing a Diverse Next Generation of Leaders in Respiratory ScienceT32HL166127 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · 2023 to 2025
$761k
VentNet: A Real-Time Multimodal Data Integration Model for Prediction of Respiratory Failure in Patients with COVID-19R01HL157985 · UNIVERSITY OF CALIFORNIA, SAN DIEGO · 2025 to 2025
$724k
Sleep Apnea Endophenotypes: One Size Does Not Fit AllR01HL154926 · UNIVERSITY OF CALIFORNIA, SAN DIEGO · 2025 to 2025
$663k
NHLBI NIH HHS R01 HL148436NHLBI NIH HHS R01 HL154926NHLBI NIH HHS R01 HL157985NHLBI NIH HHS R01 HL166485NHLBI NIH HHS T32 HL166127NIA NIH HHS R01 AG063925
6 · The paper itself

Abstract

aimIn the phase 3 SURMOUNT-OSA trials, tirzepatide treatment significantly reduced the apnea-hypopnea index (AHI) among people with moderate-to-severe obstructive sleep apnea (OSA) and obesity. We evaluated effects of tirzepatide treatment on sleep disturbance, sleep-related impairment, functioning, health-related quality of life (HRQoL), and OSA symptoms in SURMOUNT-OSA participants.

methodsSURMOUNT-OSA consisted of two randomized, placebo-controlled trials of tirzepatide (10 mg or 15 mg) or placebo for 52 weeks in participants with moderate-to-severe OSA and obesity. For participants using PAP (Study 2), PAP was withdrawn prior to assessments of polysomnography and patient-reported outcome measures (PROMs). Prespecified PROM endpoints were from baseline to Week 52. Changes in sleep-related impairment, sleep disturbance, excessive daytime sleepiness, functioning, and HRQoL were assessed using analysis of covariance. Categorical shifts in OSA symptom severity were described.

resultsAt Week 52, compared with placebo, tirzepatide-treated participants reported significantly improved Patient-Reported Outcomes Measurement Information System (PROMIS) Short-Form Sleep-related Impairment 8a scores, PROMIS Short-Form v1.0 Sleep Disturbance 8b scores, Functional Outcomes of Sleep Questionnaire Activity-Level scores, EQ-5D-5L scores, and most domains of the Short-Form 36 Health Survey, Version 2. Tirzepatide treatment was also associated with greater improvements in Patient Global Impression of Status and Patient Global Impression of Change symptom scales compared with placebo. Additionally, Study 1 participants reported significant changes in Epworth Sleepiness Scale scores.

conclusionResults indicate that in addition to objective outcomes of improved AHI, hypoxic burden associated with OSA, and cardiovascular risk factors, people with OSA reported benefits in symptoms, functioning, and HRQoL following tirzepatide treatment. CLINICALTRIALS: GOV NUMBER: NCT05412004.

Indexed as

ObesityPatient Reported Outcome MeasuresSleep Apnea, ObstructiveAdultDouble-Blind MethodFemaleHumansMaleMiddle AgedPolysomnographyQuality of LifeSeverity of Illness IndexTirzepatideTreatment OutcomeTirzepatideFunctional statusHealth-related quality of lifeObesityObstructive sleep apneaPatient-reported outcomes

Identifiers

PMID40774158
PMCPMC12720398

What Socratic holds

Texttitle and abstract
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.